Lopez-Ruz, Miguel ANavas, PurificaciónLopez-Zúñiga, Miguel AGonzalvo, Maria CarmenSampedro, AntonioPasquau, JuanHidalgo-Tenorio, CarmenJavier, RosarioCastilla, Jose A2023-01-252023-01-252016-06-30Lopez-Ruz MA, Navas P, López-Zúñiga MA, Gonzalvo MC, Sampedro A, Pasquau J, et al. Effect of Monotherapy with Darunavir/Ritonavir on Viral Load in Seminal Fluid, and Quality Parameters of Semen in HIV-1-Positive Patients. PLoS One. 2016 Jul 21;11(7):e0159305.http://hdl.handle.net/10668/10292Patients with human immunodeficiency virus type 1 (HIV-1) who receive antiretroviral therapy (ART) often achieve increased survival and improved quality of life. In this respect, monotherapy with darunavir/ritonavir (mDRV/r) can be a useful treatment strategy. This prospective study analyses the effect of mDRV/r on sperm quality and viral load in a group of 28 patients who had previously been given conventional ART and who had recorded a viral load 20 copies/ml), and that at V1, after mDRV/r treatment, this figure had fallen to 3%. The quality of seminal fluid was close to normal in 57% of patients at V0 and in 62% at V1. We conclude that, similar to ART, mDRV/r maintains HIV-1 viral load in most patients, and that there is no worsening in seminal fluid quality.enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/Antiretroviral Therapy, Highly ActiveHIV InfectionsRitonavirViral LoadAdultDarunavirDrug Therapy, CombinationHumansMaleSemenresearch article27442068open accessAdultoDarunavirHumanosMasculinoQuimioterapia combinadaSemen10.1371/journal.pone.01593051932-6203PMC4956273https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0159305&type=printablehttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4956273/pdf